Citigroup’s NGM Biopharmaceuticals, Inc. Common Stock NGM Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q2 | – | Sell |
-107,481
| Closed | -$171K | – | 4997 |
|
|
2024
Q1 | $171K | Buy |
107,481
+100,093
| +1,355% | +$159K | ﹤0.01% | 3355 |
|
|
2023
Q4 | $6.35K | Buy |
7,388
+6,333
| +600% | +$5.44K | ﹤0.01% | 4521 |
|
|
2023
Q3 | $1.13K | Sell |
1,055
-14,894
| -93% | -$15.9K | ﹤0.01% | 4321 |
|
|
2023
Q2 | $41.3K | Buy |
15,949
+14,235
| +831% | +$36.9K | ﹤0.01% | 4066 |
|
|
2023
Q1 | $6.99K | Sell |
1,714
-429
| -20% | -$1.75K | ﹤0.01% | 4180 |
|
|
2022
Q4 | $10.8K | Sell |
2,143
-8,015
| -79% | -$40.2K | ﹤0.01% | 4107 |
|
|
2022
Q3 | $133K | Sell |
10,158
-2,758
| -21% | -$36.1K | ﹤0.01% | 3264 |
|
|
2022
Q2 | $165K | Buy |
12,916
+2,477
| +24% | +$31.6K | ﹤0.01% | 3297 |
|
|
2022
Q1 | $159K | Sell |
10,439
-6,799
| -39% | -$104K | ﹤0.01% | 3522 |
|
|
2021
Q4 | $305K | Sell |
17,238
-220,589
| -93% | -$3.9M | ﹤0.01% | 3361 |
|
|
2021
Q3 | $5M | Buy |
237,827
+137,509
| +137% | +$2.89M | ﹤0.01% | 1316 |
|
|
2021
Q2 | $1.98M | Buy |
100,318
+95,997
| +2,222% | +$1.89M | ﹤0.01% | 2111 |
|
|
2021
Q1 | $125K | Sell |
4,321
-3,020
| -41% | -$87.4K | ﹤0.01% | 3603 |
|
|
2020
Q4 | $222K | Buy |
7,341
+2,125
| +41% | +$64.3K | ﹤0.01% | 3174 |
|
|
2020
Q3 | $83K | Sell |
5,216
-2,116
| -29% | -$33.7K | ﹤0.01% | 3240 |
|
|
2020
Q2 | $145K | Sell |
7,332
-3,842
| -34% | -$76K | ﹤0.01% | 3249 |
|
|
2020
Q1 | $138K | Buy |
11,174
+1,128
| +11% | +$13.9K | ﹤0.01% | 3085 |
|
|
2019
Q4 | $186K | Buy |
10,046
+9,716
| +2,944% | +$180K | ﹤0.01% | 3184 |
|
|
2019
Q3 | $4K | Sell |
330
-1,545
| -82% | -$18.7K | ﹤0.01% | 4859 |
|
|
2019
Q2 | $27K | Buy |
+1,875
| New | +$27K | ﹤0.01% | 4456 |
|